First COVID-19 drug has been assessed by G-BA
The antiviral drug remdesivir (brand name: Veklury) has been the first drug targeting COVID-19, which has undergone an early benefit assessment. It
Tag: G-BA
What is reference pricing?
If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,
The process of method assessments in Germany
The G-BA, physicians, hospitals, SHI funds or patient organizations can request the assessment of a new method. If the request was accepted,
The G-BA starts the development of a new DMP for obesity
This new DMP for obesity should consider and combine various therapeutic approaches to offer the best possible care, treat patients with obesity
NUB method assessments to become faster
Early benefit assessments are completed within 12 months, while method assessments used to take around 3 years. In 2020, the G-BA introduced